News Release

Translation contracts signed

Date: 2000/03/09

Translation - International Wex Technologies Inc., is pleased to announce that the 2nd phase of their planned program to make applications before the major world regulatory bodies for pharmaceutical approval has commenced. All the research data generated to date in China is now being placed with Canadian and U.S. Chinese to English certified professional translators. Completion is expected by late spring of this year. Dr. S. Lu, of our Vancouver office, is directing this phase and will verify the translations for accuracy. This most essential step will bring forward the time line for the filing of the Investigational New Drug Application with USFDA on Tetrodin (HT).

Tetrodin (HT) has been developed by the company primarily as a treatment for the symptoms associated with withdrawal from all opiate addictions such as morphine, opium, heroin and methadone. It is a non-narcotic pharmaceutical that has proven to be safe and effective and functions well in both primary withdrawal treatment and abstinence maintenance (longer term use) of drug addiction. The company has also begun tests on the usage of Tetrodin (HT) as a potent analgesic.

For additional information on Tetrodin (HT), view the IWT website at http://www.wextech.ca or call Howard Milne , V. P. Shareholder Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary